Vir Biotechnology, Inc. Form 8-K (Jan. 29, 2020)

Summary

Form 8-K Item 8.01, Other Events, filed by Vir Biotechnology, Inc. The report states that on January 29, 2020, Dr. George Scangos, President and Chief Executive Officer, gave interviews to several news media outlets about the company's efforts to develop a therapy for 2019-nCoV, also known as "Wuhan coronavirus". Dr. Scangos said the company believes it will know within the next weeks to months whether any of its current antibodies are effective against the Wuhan coronavirus. Dr. Scangos also disclosed that manufacturing would take an additional number of months, and that the expected process could total approximately 10 months, although actual timelines are difficult to predict.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT
REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 29, 2020

Vir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-39083 | 81-2730369
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)

499 Illinois Street, Suite 500

San Francisco, California 94158

(Address of principal executive offices, including zip code)

(415) 906-4324

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.0001 par value per share | VIR | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth
company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 29, 2020, Dr. George Scangos, President and Chief Executive Officer of Vir Biotechnology, Inc. (the “Company”), provided
interviews with several news media outlets to discuss the Company’s efforts to develop a therapy for 2019-nCoV, also known as “Wuhan coronavirus”. In the interviews, Dr. Scangos discussed the timing of potentially developing a
therapy and stated that the Company believes that it will know whether any of its current antibodies are effective against the Wuhan coronavirus in the next weeks to months. Dr. Scangos also disclosed that manufacturing would take an additional
number of months, and that the expected process could total approximately 10 months, although actual timelines are difficult to predict. In addition, the Company is in discussions with manufacturers and regulators regarding expediting the
manufacture and regulatory pathway for any potential therapy.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “potential” and similar expressions (as well as other
words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this
Current Report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this Current Report include statements
regarding the timing of development, manufacture and regulatory approval of a potential therapy to address the Wuhan coronavirus. Many factors may cause differences between current expectations and actual results including unexpected safety or
efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, difficulties identifying or entering into
contracts with manufacturers, unexpected problems with the manufacturing process, regulatory delays and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the
forward-looking statements in this Current Report are discussed in the Company’s filings with the Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, the
Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

VIR BIOTECHNOLOGY, INC.
Date: January 30, 2020 | By: | /s/ Howard Horn
Howard Horn
Chief Financial Officer

File and source

File

SEC_VIR_8-K_filed2020-01-30_0001193125-20-018960.htm

Size

18,167 bytes

SHA-256

1b470bba8c90089ed98469f4e2a579e0517fb9a9496f214f9af319569acc2cab

Our copy

SEC_VIR_8-K_filed2020-01-30_0001193125-20-018960.htm

Original

www.sec.gov